Effects of Age and Immune Landscape on Outcome in HER2-Positive Breast Cancer in the NCCTG N9831 (Alliance) and NSABP B-31 (NRG) Trials
暂无分享,去创建一个
D. Serie | E. Perez | E. Thompson | Afshin Mashadi-Hossein | K. Pogue-Geile | Y. Lou | K. Knutson | S. Warren | S. Chumsri | Zhuo Li | A. Moreno-Aspitia | G. Colón-Otero | Aixa E Soyano-Muller
[1] E. Winer,et al. Tailoring Adjuvant Endocrine Therapy for Premenopausal Breast Cancer , 2018, The New England journal of medicine.
[2] Xin Hu,et al. Impact of hormone receptor status and distant recurrence-free interval on survival benefits from trastuzumab in HER2-positive metastatic breast cancer , 2017, Scientific Reports.
[3] Patrick Danaher,et al. Gene expression markers of Tumor Infiltrating Leukocytes , 2016, Journal of Immunotherapy for Cancer.
[4] J. Forbes,et al. Aromatase inhibitors versus tamoxifen in early breast cancer: patient-level meta-analysis of the randomised trials , 2015, The Lancet.
[5] C. Fan,et al. Gene expression in “young adult type” breast cancer: a retrospective analysis , 2015, Oncotarget.
[6] T. Nielsen,et al. The evaluation of tumor-infiltrating lymphocytes (TILs) in breast cancer: recommendations by an International TILs Working Group 2014. , 2015, Annals of oncology : official journal of the European Society for Medical Oncology.
[7] Jong-Hyeon Jeong,et al. Trastuzumab plus adjuvant chemotherapy for human epidermal growth factor receptor 2-positive breast cancer: planned joint analysis of overall survival from NSABP B-31 and NCCTG N9831. , 2014, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[8] Molin Wang,et al. Prognostic value of tumor-infiltrating lymphocytes in triple-negative breast cancers from two phase III randomized adjuvant breast cancer trials: ECOG 2197 and ECOG 1199. , 2014, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[9] S Michiels,et al. Tumor infiltrating lymphocytes are prognostic in triple negative breast cancer and predictive for trastuzumab benefit in early breast cancer: results from the FinHER trial. , 2014, Annals of oncology : official journal of the European Society for Medical Oncology.
[10] E. Winer,et al. Effect of age on breast cancer outcomes in women with human epidermal growth factor receptor 2-positive breast cancer: results from a herceptin adjuvant trial. , 2013, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[11] Stefan Michiels,et al. Prognostic and predictive value of tumor-infiltrating lymphocytes in a phase III randomized adjuvant breast cancer trial in node-positive breast cancer comparing the addition of docetaxel to doxorubicin with doxorubicin-based chemotherapy: BIG 02-98. , 2013, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[12] M. Barton. Hormone receptor status affects locoregional control in HER2‐positive breast cancer treated with trastuzumab , 2012, CA: a cancer journal for clinicians.
[13] Paul C. Boutros,et al. NanoStringNorm: an extensible R package for the pre-processing of NanoString mRNA and miRNA data , 2012, Bioinform..
[14] E. Perez,et al. Sequential versus concurrent trastuzumab in adjuvant chemotherapy for breast cancer. , 2011, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[15] R. Gress,et al. The aging immune system and its relationship with cancer. , 2011, Aging health.
[16] Jong-Hyeon Jeong,et al. Four-year follow-up of trastuzumab plus adjuvant chemotherapy for operable human epidermal growth factor receptor 2-positive breast cancer: joint analysis of data from NCCTG N9831 and NSABP B-31. , 2011, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[17] A. Jemal,et al. Cancer Statistics, 2010 , 2010, CA: a cancer journal for clinicians.
[18] H. Komatsu. [Antibody therapy in cancer]. , 2010, Nihon rinsho. Japanese journal of clinical medicine.
[19] A. Bleyer,et al. Breast cancer before age 40 years. , 2009, Seminars in oncology.
[20] J. Marks,et al. Young age at diagnosis correlates with worse prognosis and defines a subset of breast cancers with shared patterns of gene expression. , 2008, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[21] Greg Yothers,et al. Trastuzumab plus adjuvant chemotherapy for operable HER2-positive breast cancer. , 2005, The New England journal of medicine.
[22] M. Owens,et al. HER2 amplification ratios by fluorescence in situ hybridization and correlation with immunohistochemistry in a cohort of 6556 breast cancer tissues. , 2004, Clinical breast cancer.
[23] D. Hughes,et al. Significant presence of terminally differentiated T cells and altered NF-κB and I-κBα interactions in healthy ageing , 2004, Experimental Gerontology.
[24] A. Luini,et al. Very young women (<35 years) with operable breast cancer: features of disease at presentation. , 2002, Annals of oncology : official journal of the European Society for Medical Oncology.
[25] E. Leventhal,et al. Aging, immunity, and cancer. , 2000, Cancer control : journal of the Moffitt Cancer Center.
[26] L. Presta,et al. Inhibitory Fc receptors modulate in vivo cytoxicity against tumor targets , 2000, Nature Medicine.
[27] D. Neuberg,et al. Relationship of patient age to pathologic features of the tumor and prognosis for patients with stage I or II breast cancer. , 1994, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[28] B. Asselain,et al. Age as prognostic factor in premenopausal breast carcinoma , 1993, The Lancet.
[29] W. McGuire,et al. Human breast cancer: correlation of relapse and survival with amplification of the HER-2/neu oncogene. , 1987, Science.
[30] E. Perez,et al. Association of Stromal Tumor-Infiltrating Lymphocytes With Recurrence-Free Survival in the N9831 Adjuvant Trial in Patients With Early-Stage HER2-Positive Breast Cancer. , 2016, JAMA oncology.
[31] Carlos L. Arteaga,et al. Treatment of HER2-positive breast cancer: current status and future perspectives , 2012, Nature Reviews Clinical Oncology.
[32] Carsten Denkert,et al. Tumor-associated lymphocytes as an independent predictor of response to neoadjuvant chemotherapy in breast cancer. , 2010, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[33] G. Hortobagyi,et al. Prognosis of women with metastatic breast cancer by HER2 status and trastuzumab treatment: an institutional-based review. , 2010, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[34] D. Hughes,et al. Significant presence of terminally differentiated T cells and altered NF-kappaB and I-kappaBalpha interactions in healthy ageing. , 2004, Experimental gerontology.
[35] B. Haynes,et al. The role of the thymus in immune reconstitution in aging, bone marrow transplantation, and HIV-1 infection. , 2000, Annual review of immunology.
[36] D. Allred,et al. Breast cancer outcome and predictors of outcome: are there age differentials? , 1994, Journal of the National Cancer Institute. Monographs.
[37] N. Dubrawsky. Cancer statistics , 1989, CA: a cancer journal for clinicians.